Allergic coronary events are broader than epicardial spasm
Kounis syndrome remains one of the most easily missed causes of acute coronary syndromes because the trigger can look like a routine allergic reaction while the cardiac presentation unfolds at the same time. In the modern literature, the syndrome sits at the intersection of immunology, coronary physiology, and emergency cardiology, where mast cell activation and hypersensitivity reactions can produce either reversible vasospasm or thrombotic coronary injury.
The review places Kounis syndrome in sharper clinical focus by separating the classic vasospastic presentation from the thrombotic forms that involve atherosclerotic plaque, a coronary stent, or a bypass graft. Type I disease occurs in patients without known coronary artery disease and can present as pure vasomotor ischemia. Type II and type III variants reflect a more unstable coronary substrate, while type IV involves bypass graft pathology. The practical message is direct: an allergic trigger does not mean the myocardial ischemia is benign, and a normal or near-normal angiogram does not exclude clinically significant coronary involvement.
Immune mediator release links allergy to myocardial ischemia
The pathophysiology is anchored in immune cell activation. Allergic and hypersensitivity reactions drive the release of vasoactive and prothrombotic mediators, which can constrict coronary arteries, destabilize plaque, and promote thrombosis. Histamine, leukotrienes, platelet-activating pathways, and other inflammatory signals create a biologically plausible route from urticaria, bronchospasm, or drug hypersensitivity to chest pain, electrocardiographic change, and myocardial injury.
A single sentence captures the danger: coronary ischemia may begin before the allergic episode appears fully resolved.
This mechanistic framework also explains why the syndrome does not always behave like classic obstructive coronary disease. In type I disease, spasm can dominate the clinical picture and then recede, leaving little structural evidence behind if the patient is imaged late or without targeted functional testing. In type II and type III disease, the same allergic cascade can collide with vulnerable plaque or a coronary implant, turning inflammation into thrombosis rather than isolated vasoconstriction. The review treats these as related but not interchangeable entities, and that distinction matters at the bedside when clinicians decide whether the event is transient vasomotor instability or a true coronary thrombotic emergency.
Normal angiography does not rule out coronary involvement
One of the most important clinical observations is that angiographically documented epicardial spasm is seen in only a minority of patients. Normal or non-obstructive coronary arteries are encountered frequently, which can mislead teams that rely too heavily on anatomic angiography alone. This creates a diagnostic blind spot, especially in patients whose symptoms improve quickly after treatment of the allergic reaction.
The review argues for a broader diagnostic approach that incorporates symptoms, biochemical testing, electrocardiography, echocardiography, coronary angiography, multimodality imaging, and invasive assessment in selected cases. This is not a theoretical upgrade in methodology; it is a response to the syndrome’s biology. If the main injury mechanism is dynamic vasoconstriction or microvascular dysfunction, a static lumenogram can miss the process entirely.
Emerging evidence from provocative testing, invasive coronary functional assessment, cardiac magnetic resonance, and nuclear imaging points toward coronary microvascular dysfunction as a substantial contributor to the phenotype. That finding expands the traditional view of Kounis syndrome beyond the obvious epicardial spasm model. The coronary tree can be functionally injured at the microcirculatory level even when the large vessels look unobstructed, and that helps explain why some patients develop ischemic symptoms without dramatic angiographic obstruction.
Microvascular dysfunction may explain the cases that angiography misses
The microvascular hypothesis is especially important because it offers a pathophysiologic bridge between allergic inflammation and ischemia that does not depend on a visible epicardial lesion. Small-vessel dysregulation can impair perfusion, prolong ischemia, and generate symptoms that resemble classic acute coronary syndromes. Cardiac magnetic resonance and nuclear imaging provide a way to detect myocardial involvement when standard angiography fails to show the expected culprit lesion.
This perspective also strengthens the argument that type I Kounis syndrome belongs within the myocardial infarction with non-obstructive coronary arteries, or MINOCA, spectrum. The syndrome behaves like an allergic vasomotor acute coronary syndrome, and not merely as an unusual form of chest pain during anaphylaxis. Reframing the condition this way may improve recognition in emergency departments, catheterization laboratories, and general cardiology practice, where diagnostic inertia often favors obstructive disease first.
Clinical classification should reflect the mechanism, not just the angiogram
The review presses for future diagnostic classifications and clinical practice guidelines to recognize type I disease as a distinct allergic vasomotor acute coronary syndrome. That proposal follows directly from the accumulated clinical pattern: allergic trigger, ischemic symptoms, frequent non-obstructive coronary findings, and evidence that microvascular dysfunction can be part of the same process. A classification system built only around visible coronary plaque would miss a large part of the syndrome’s biology.
Direct clinical consequence is unavoidable here. A patient with an allergic reaction and ischemic ECG changes may need evaluation for both hypersensitivity and myocardial ischemia, rather than treatment of one condition at the expense of the other. Careful interpretation of troponin dynamics, hemodynamics, and imaging becomes essential, because the coronary event may be transient, focal, diffuse, or thrombotic depending on the variant involved.
Therapeutically, the review remains cautious and pragmatic. Management must account for the allergic trigger while also addressing coronary ischemia, but the publication does not reduce the syndrome to a simple algorithm. The combination of vasospasm, plaque instability, and potential microvascular injury makes one-size-fits-all care unlikely to work across all variants. What the literature supports most strongly is recognition: Kounis syndrome should be considered when an allergic or hypersensitivity reaction coincides with acute coronary symptoms, especially when the coronary anatomy does not match the severity of the presentation.
Diagnostic vigilance is the main unmet need
The greatest gap is not conceptual; it is operational. Routine practice still under-recognizes the syndrome, and implementation of comprehensive diagnostic workups remains limited. That leaves many patients categorized under broader acute coronary syndrome labels without the allergic trigger being fully integrated into their cardiac diagnosis.
The review closes that gap by aligning the syndrome with contemporary coronary medicine rather than treating it as a rare curiosity. Its most valuable contribution is the insistence that Kounis syndrome has a real mechanistic basis, a recognizable clinical spectrum, and a place in the MINOCA framework. Future work will need to define which imaging and functional tests best capture the microvascular component, how to separate variants at presentation, and how classification should change when the coronary lesion is dynamic rather than fixed.